聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎45例的疗效评价

Curative Effect of Pegylated Interferon α-2a Combined with Ribavirin in the Treatment of 45 Cases of Chronic Hepatitis C

目的探讨聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者的临床疗效。方法选择我院2010年1月至2013年1月间90例慢性丙型肝炎患者,随机分成对照组和观察组各45例。对照组给予重组人干扰素α2b联合利巴韦林治疗,观察组给予聚乙二醇干扰素α-2a联合利巴韦林治疗,比较两组的临床疗效。结果观察组治疗24周HCV-RNA转阴率为73.33%,高于对照组的51.11%,差异有统计学意义(P<0.05);观察组治疗24周、48周ALT复常率均高于对照组,差异有统计学意义(P<0.05);两组患者均未出现严重药物不良反应。结论聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者疗效佳,具有良好的安全性。

Objective To explore the clinical efficacy ofpegylated interferon a-2a combined with ribavirin therapy in the treatment of patients with chronic hepatitis C. Methods 90 patients with chronic hepatitis C in our hospital from January 2010 to January 2013 were selected and randomly divided into the control group and observation group, with 45 cases in each group. Patients in the control group received the combination treatment with recombinant human interferon a2b and ribavirin, while patients in the observation group received the combination treatment with pegylated interferon α-2a and ribavirin. The curative effects of two groups were compared. Results The HCV-RNA negative rate at 24 weeks of treatment was 73.33% in the observation group, significantly higher than 51.11% in the control group （P 〈0.05）. The ALT recovery rates at 24 and 48 weeks of treatment in the observation group were higher than those in the control group, with statistically significant difference （P 〈0.05）. No severe adverse reaction was found in two groups. Conclusions Pegylated interferon α-2a combined with ribavirin therapy in patients with chronic hepatitis C has good curative effect and safety.